Moderna Leads S&P 500 with Bird Flu Vaccine Hopes
Moderna's stock tops S&P 500, fueled by optimism around its experimental bird flu vaccine. Explore why investors are excited about this potential breakthrough.
Topic
biotechnology
A collection of 5 issues
Company Advances H5N1 Vaccine Development
Explore the company's groundbreaking efforts in developing a vaccine for H5N1. Stay informed with the latest updates on avian influenza research.
Moderna's Stock Soars Amid Bird-Flu Vaccine Efforts
Moderna's stock rises as it develops a bird-flu vaccine following a U.S. death. Stay updated on vaccine advancements and stock movements.
Sangamo Reclaims Rights to Hemophilia Gene Therapy from Pfizer
Sangamo Therapeutics regains rights to giroctocogene fitelparvovec after Pfizer's successful Phase 3 trials, marking a pivotal shift in hemophilia gene therapy.
D. Boral Capital Starts Avita Medical at Buy with $25 Target
D. Boral Capital initiates coverage on Avita Medical (RCEL) with a Buy rating and $25 target, citing promising clinical results in biotechnology.